|A product of the Society of Infectious Diseases Pharmacists Education Center (SIDPEC)|
Ryan Shields and Erin McCreary discuss notable infectious diseases publications from the first half of 2020.
- Rybak MJ, et al. Am J Health Syst Pharm. 2020 May 19;77(11):835-864. doi: 10.1093/ajhp/zxaa036.
- Scheetz MH. Am J Health Syst Pharm. 2020 May 19;77(11):810-811. doi: 10.1093/ajhp/zxaa076.
- Alosaimy S, et al. Clin Infect Dis. 2020 July 27;ciaa1039. doi: 10.1093/cid/ciaa1039.
- Rhee C, et al. Clin Infect Dis. 2020 May 6;ciaa059. doi: 10.1093/cid/ciaa059.
- Heil EL, et al. Pharmacotherapy. 2020 Apr;40(4):368-371. doi: 10.1002/phar.2384.
- Townsend SR, et al. Clin Infect Dis. 2020 May 6;ciaa458. doi: 10.1093/cid/ciaa458.
- Satlin MJ, et al. Clin Infect Dis. 2020 Feb 13;ciaa121. doi: 10.1093/cid/ciaa121.
- Pogue JM, et al. Antimicrob Agents Chemother. 2020 Jan 27;64(2):e01495-19. doi: 10.1128/AAC.01495-19.
- Ambrose PG, et al. Open Forum Infect Dis. 2020 Mar 13;7(7):ofaa084. doi: 10.1093/ofid/ofaa084.
- Singh N, et al. JAMA. 2020 Apr 14;323(14):1378-1387. doi: 10.1001/jama.2020.3138.
- van Delden C, et al. Clin Infect Dis. 2020 Jan 9;ciz1113. doi: 10.1093/cid/ciz1113.
- Niederman MS, et al. Lancet Infect Dis. 2020 Mar;20(3):330-340. doi: 10.1016/S1473-3099(19)30574-2.
- von Dach E, et al. JAMA. 2020 Jun 2;323(21):2160-2169. doi: 10.1001/jama.2020.6348.
- Mergenhagen KA, et al. Antimicrob Agents Chemother. 2020 Feb 21;64(3):e02167-19. doi: 10.1128/AAC.02167-19.
The target audience for this activity includes pharmacists. At the completion of this activity, the participant will be able to:
- Discuss notable, non-COVID-19 publications in infectious diseases from January to June 2020.
- Describe the impact of these publications on infectious diseases clinical practice.
Erin K. McCreary, PharmD, BCPS, BCIDP
Antimicrobial Stewardship/Infectious Diseases Clinical Pharmacist
University of Pittsburgh Medical Center
Ryan K. Shields, PharmD, MS
Associate Professor of Medicine
University of Pittsburgh
Release Date: September 4, 2020
Expiration Date: September 4, 2023
This activity is jointly provided by ProCE, Inc. and the Society of Infectious Diseases Pharmacists. ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-20-357-H01-P has been assigned to this home study, knowledge-based activity. This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. Completion of the evaluation and the post-test with a score of 70% or higher are required to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.
The Society of Infectious Diseases Pharmacists (SIDP) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certified infectious diseases pharmacist (BCIDP) credit. A BCIDP statement of credit will be issued online upon successful completion of a post-test and online evaluation. The post-test must be successfully completed in only one attempt. No partial credit will be given. BCIDP accreditation begins 09/04/2020 for this activity and is available for one year from this date.
Recertification Criteria for Infectious Diseases Pharmacy: BCIDP recertifying via continuing education are required to earn 100 hours of continuing education credit provided by the joint program offered by the Society of Infectious Diseases Pharmacists (SIDP), American College of Clinical Pharmacy (ACCP) and/or the American Society of Health-System Pharmacists (ASHP). Infectious Diseases Pharmacy Specialty Recertification Courses offered by any of the approved providers may only be completed for recertification credit up to two times, in nonconsecutive years, during the 7-year recertification cycle. Candidates should note that there are expiration dates associated with earning BPS recertification credit. BPS will only award recertification credit for modules based on the completion and submission date of the post-test assessment. For example, a module completed and submitted on October 20 of a particular year will only be credited for that year, even if the due date of the post-test is in January of the following year. View all recertification criteria on the BPS website at https://www.bpsweb.org/recertification/recertification-by-continuing-education
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Dr. McCreary has no relevant commercial or financial relationships to disclose. Dr. Shields has served as a consultant for Allergan, Entasis, Merck, Shionogi, and Summit; has served as a speaker for Menarini and Pfizer; has received research funds as an Investigator for Allergan, Merck, Shionogi, Tetraphase, and Venatorx.
This activity is provided by ProCE, Inc. and SIDP.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.